Trial Profile
A multi-center prospective randomized phase III trial to determine the benefit of adjuvant chemotherapy using gemcitabine and cisplatin in nasopharyngeal carcinoma patients with residual EBV [Epstein-Barr virus] DNA following primary radiotherapy with or without concurrent cisplatin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Cisplatin
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 09 Feb 2022 Status changed from active, no longer recruiting to completed.
- 13 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 13 Jan 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.